DK1313504T3 - Fremgangsmåder og sammensætninger til hæmning af angiogenese - Google Patents

Fremgangsmåder og sammensætninger til hæmning af angiogenese

Info

Publication number
DK1313504T3
DK1313504T3 DK01968398T DK01968398T DK1313504T3 DK 1313504 T3 DK1313504 T3 DK 1313504T3 DK 01968398 T DK01968398 T DK 01968398T DK 01968398 T DK01968398 T DK 01968398T DK 1313504 T3 DK1313504 T3 DK 1313504T3
Authority
DK
Denmark
Prior art keywords
methods
compounds
inhibiting angiogenesis
compositions
endothelial cells
Prior art date
Application number
DK01968398T
Other languages
Danish (da)
English (en)
Inventor
Mahesh C Sharma
George P Tuszynski
Original Assignee
Philadelphia Health & Educatio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health & Educatio filed Critical Philadelphia Health & Educatio
Application granted granted Critical
Publication of DK1313504T3 publication Critical patent/DK1313504T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK01968398T 2000-09-01 2001-09-04 Fremgangsmåder og sammensætninger til hæmning af angiogenese DK1313504T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22966700P 2000-09-01 2000-09-01
US27720401P 2001-03-20 2001-03-20
PCT/US2001/027310 WO2002017857A2 (en) 2000-09-01 2001-09-04 Methods and compositions for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
DK1313504T3 true DK1313504T3 (da) 2007-02-26

Family

ID=26923501

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01968398T DK1313504T3 (da) 2000-09-01 2001-09-04 Fremgangsmåder og sammensætninger til hæmning af angiogenese

Country Status (9)

Country Link
EP (1) EP1313504B1 (de)
JP (1) JP2004507482A (de)
AT (1) ATE346607T1 (de)
AU (1) AU2001288648A1 (de)
CA (1) CA2421503A1 (de)
DE (1) DE60124927T2 (de)
DK (1) DK1313504T3 (de)
ES (1) ES2272537T3 (de)
WO (1) WO2002017857A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134885D1 (de) 2000-11-28 2008-08-28 David M Waisman Antiangiogene polypeptide
WO2004054517A2 (en) 2002-12-13 2004-07-01 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
EP1670510A1 (de) * 2003-09-24 2006-06-21 Peter Krammer Antikörper gegen annexine, ihre verwendung in der therapie und diagnose, verwendung von annexinen für therapie und diagnose
DE102004046540A1 (de) * 2004-09-21 2006-04-06 Eberhard-Karls-Universität Tübingen Universitätsklinikum Annexin-Modulation und Infektionsresistenz
US20060111423A1 (en) * 2004-10-26 2006-05-25 Zeligs Michael A Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
WO2012048190A1 (en) * 2010-10-08 2012-04-12 Regents Of The University Of Minnesota Annexin ii compositions and methods
CA2930567C (en) 2013-11-13 2023-09-26 Regents Of The University Of Minnesota Annexin ii variant compositions and methods
EP3045470A1 (de) 2015-01-15 2016-07-20 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulatoren der Funktion der Kerndomäne von Annexinen und Verwendungen davon in der Autoimmun- und/oder Krebstherapie
PT3468621T (pt) 2016-06-10 2022-12-21 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts O domínio central das anexinas e suas utilizações no fornecimento e vacinação de antigénios

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051364A (en) * 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
JP2002507405A (ja) * 1998-03-27 2002-03-12 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 低酸素誘導ヒト遺伝子、タンパク質およびそれらの使用
DE69942207D1 (de) * 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins

Also Published As

Publication number Publication date
ATE346607T1 (de) 2006-12-15
ES2272537T3 (es) 2007-05-01
DE60124927D1 (de) 2007-01-11
EP1313504A2 (de) 2003-05-28
EP1313504B1 (de) 2006-11-29
DE60124927T2 (de) 2007-09-20
WO2002017857A2 (en) 2002-03-07
EP1313504A4 (de) 2004-06-30
WO2002017857A3 (en) 2002-06-13
AU2001288648A1 (en) 2002-03-13
CA2421503A1 (en) 2002-03-07
JP2004507482A (ja) 2004-03-11

Similar Documents

Publication Publication Date Title
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
PT1187918E (pt) Antagonistas de tek
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
TR199901077A2 (en) �spen�iyari form�lasyonlar.
DK1450606T3 (da) Synergistiske sammensætninger til behandling af såsæd
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1250152T3 (da) Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
DK1313504T3 (da) Fremgangsmåder og sammensætninger til hæmning af angiogenese
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
WO2002018341A3 (en) Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
SE9801494D0 (sv) Novel use
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser